查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087469

RNA干擾技術市場：2026-2032年全球市場預測（依分子類型、給藥途徑、遞送方式、應用及最終用戶分類）

RNA Interference Technology Market by Molecule Type, Route Of Administration, Delivery Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年， RNA干擾技術市場將成長至 82.6 億美元，複合年成長率為 12.96%。

主要市場統計數據
基準年 2025 35.2億美元
預計年份：2026年 39.5億美元
預測年份 2032 82.6億美元
複合年成長率 (%) 12.96%

RNA干擾（RNAi）是一種成熟的基因沉默平台，它利用小干擾RNA（siRNA）、 微型RNA調控以及相關的雙鏈RNA技術，在有害蛋白質產生之前減少致病基因靜默傳訊RNA 。自1998年RNAi機制被發現，並於2006年獲得諾貝爾生理學或醫學獎以來，該領域已從基礎生物學發展到如今已通過核准的RNAi療法、農業生物技術、功能基因組學和精準醫學等領域。

商業性發展勢頭得益於帕替西蘭、吉博西蘭、盧馬西蘭、因克利西蘭、武曲西蘭和奈多西蘭等siRNA藥物的法規核准，這些藥物證明了RNAi在罕見疾病、心血管代謝疾病、腎臟和代謝性疾病以及肝臟靶向疾病中的臨床價值。市場日益呈現出遞送技術創新的趨勢，特別是靶向肝細胞的GalNAc偶聯物、能夠到達更廣泛組織的脂質奈米顆粒系統以及用於提高效力、持久性和耐受性的改進型寡核苷酸化學。

RNAi領域的變革性變化

RNA干擾技術正從專注於罕見疾病治療轉向更廣泛的慢性病應用，其中心血管代謝疾病、腎臟疾病、眼科疾病、神經系統疾病、腫瘤和感染疾病等領域的研發管線備受關注。與傳統的小分子化合物和單株抗體相比，RNA干擾技術具有持續基因靜默、給藥頻率低和靶向特異性高等提案，尤其適用於疾病的生物機制可歸因於基因明確的靶點或以往難以治療的靶點的情況。

人工智慧的累積影響

人工智慧透過改進標靶優先排序、siRNA序列設計、脫靶預測、毒性篩檢和遞送製劑最佳化，正在加速RNAi藥物的發現。基於轉錄組、蛋白質組、結構、基因組和臨床資料集訓練的機器學習模型有助於識別疾病相關基因，並減少不太可能進入成本高昂的實驗室檢驗階段的候選藥物數量。

對關鍵區域的洞察

北美憑藉其龐大的生物技術生態系統、FDA在寡核苷酸療法方面的經驗、雄厚的創業融資、學術醫療中心和完善的臨床試驗基礎設施，仍然是RNA干擾技術的領先中心。歐洲受益於歐洲藥品管理局（EMA）的核准流程、卓越的學術水平、國家基因組醫學舉措和跨境研究項目，而歐盟則支持先進療法、藥物安全監測和統一的藥品生產標準。

關鍵的群體特定見解

由於七國集團（G7）擁有成熟的監管機構、報銷體系、智慧財產權保護、先進的臨床網路和完善的藥品生產標準，它們在RNAi的商業化過程中發揮核心作用。歐盟正透過協調一致的法律規範、多邊研究資助、衛生技術評估（HTA）合作以及藥品品管框架來加強一致性。同時，在北約成員國市場，確保生物製造、衛生安全、戰略儲備和供應鏈連續性方面的韌性是當務之急。

主要國家的概況

憑藉FDA批准的siRNA療法、大型生物技術叢集、NIH資助的研究、專業的臨床研究人員以及充足的資金籌措，美國引領著RNA干擾技術的全球發展。加拿大在學術研究、公共資助的基因組學研究和臨床研究網路方面發揮著重要作用，而墨西哥則是北美重要的准入和臨床試驗市場。巴西憑藉其龐大的醫療保健系統、公共研究機構、專科醫院以及在獲取複雜生技藥品的經驗，為拉丁美洲的發展機會奠定了基礎。

為行業領導者提供的實用建議

產業領導者應優先發展能夠將RNAi的應用範圍擴展到肝臟以外的遞送平台，同時確保其安全性、可重複的生產過程和明確的動態學證據。各機構應投資於GalNAc、脂質奈米顆粒、局部遞送、配體發現、核內體逃脫技術以及可擴展的寡核苷酸合成，以在競爭日益激烈的環境中脫穎而出。

調查方法

對RNA干擾技術的評估以系統化的調查方法為基礎，該方法結合了二手調查、一手訪談、資料檢驗和專家檢驗。輸入資料包括法規核准、臨床試驗註冊資訊、科學文獻、專利趨勢、企業資訊披露、政府醫療保健數據、報銷趨勢、公共資金支持措施以及與RNA干擾技術相關的生物製藥投資趨勢。

結論

RNA干擾技術已從一項突破性的生物學發現發展成為一種臨床驗證有效的療法，並具有日益成長的商業性價值。已通過核准的siRNA療法已證明，目標基因定序能夠產生持久療效，而遞送系統的進步正使其應用於新的疾病領域和更廣泛的患者群體。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章RNA干擾技術市場：依分子類型分類

  • 微型RNA（miRNA）
  • 短髮夾RNA（shRNA）
    • 非病毒載體shRNA
    • 病毒傳播的shRNA
  • 小干擾RNA（siRNA）
    • 結合型siRNA
    • 未結合的siRNA

第8章RNA干擾技術市場：依給藥途徑分類

  • 肌肉內注射
  • 鞘內（IT）給藥
  • 靜脈注射

第9章RNA干擾技術市場：依遞送方式分類

  • 直接遞送裸露的RNAi
  • 以外泌體為基礎的RNAi療法
  • 利用奈米顆粒進行遞送
  • 利用病毒載體進行遞送

第10章： RNA干擾技術市場：依應用領域分類

  • 藥物發現
    • 先導藥物最適化
    • 目標識別
  • 研究與開發
    • 基因功能研究
    • 路徑分析
  • 治療

第11章RNA干擾技術市場：依最終用戶分類

  • 受託研究機構
  • 醫院和診所
  • 製藥和生物技術公司

第12章RNA干擾技術市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章RNA干擾技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章RNA干擾技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • ADARx Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Arbutus Biopharma Corporation
  • Arcturus Therapeutics Holdings Inc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca PLC
  • Avidity Biosciences Inc
  • Benitec Biopharma Inc
  • BioNTech SE
  • City Therapeutics Inc
  • Genevant Sciences Ltd
  • Intellia Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Moderna Inc
  • Novartis AG
  • Novo Nordisk A/S
  • OliX Pharmaceuticals Inc
  • Phio Pharmaceuticals Corp
  • ProQR Therapeutics NV
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics Inc
  • Silence Therapeutics PLC
  • Sirnaomics Inc
  • Suzhou Ribo Life Science Co., Ltd
  • Vir Biotechnology Inc
  • Wave Life Sciences Ltd
Product Code: MRR-0375F3EAA810

The RNA Interference Technology Market is projected to grow by USD 8.26 billion at a CAGR of 12.96% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.52 billion
Estimated Year [2026] USD 3.95 billion
Forecast Year [2032] USD 8.26 billion
CAGR (%) 12.96%

RNA interference technology is a validated gene-silencing platform that uses small interfering RNA, microRNA modulation, and related double-stranded RNA approaches to reduce disease-driving messenger RNA before harmful proteins are produced. Since the RNAi mechanism was described in 1998 and recognized with the 2006 Nobel Prize in Physiology or Medicine, the field has moved from discovery biology to approved RNAi therapeutics, agricultural biotechnology, functional genomics, and precision medicine.

Commercial momentum is supported by regulatory approvals for siRNA drugs such as patisiran, givosiran, lumasiran, inclisiran, vutrisiran, and nedosiran, which demonstrate the clinical value of RNAi for rare diseases, cardiometabolic disorders, renal and metabolic conditions, and liver-targeted indications. The market is increasingly defined by delivery innovation, especially GalNAc conjugates for hepatocyte targeting, lipid nanoparticle systems for broader tissue access, and improved oligonucleotide chemistry that enhances potency, durability, and tolerability.

Transformative Shifts in the RNAi Landscape

The RNA interference landscape is shifting from specialized rare-disease programs toward broader chronic-disease opportunities, with cardiometabolic, renal, ophthalmic, neurological, oncology, and infectious-disease pipelines gaining visibility. Durable gene silencing, infrequent dosing, and target specificity are strengthening the value proposition against conventional small molecules and monoclonal antibodies, particularly where disease biology is driven by genetically defined or previously undruggable targets.

The most transformative change is delivery. GalNAc-siRNA conjugates have reduced dosing frequency and improved liver targeting, while lipid nanoparticles, extrahepatic ligands, inhaled, intrathecal, intravitreal, and local delivery approaches are expanding the addressable target space. At the same time, regulators are demanding rigorous off-target, immunogenicity, chemistry-manufacturing-control, biodistribution, drug-drug interaction, and long-term safety evidence, making platform quality a core competitive advantage.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating RNAi discovery by improving target prioritization, siRNA sequence design, off-target prediction, toxicity screening, and delivery formulation optimization. Machine learning models trained on transcriptomic, proteomic, structural, genomic, and clinical datasets can help identify disease-relevant genes and reduce the number of low-probability candidates entering costly laboratory validation.

AI is also strengthening precision medicine strategies by supporting biomarker discovery, patient segmentation, trial enrichment, and real-world evidence analysis for RNAi therapeutics. However, AI does not replace experimental validation; high-confidence RNAi programs still require reproducible in vitro, in vivo, pharmacokinetic, pharmacodynamic, manufacturing, and clinical evidence to confirm durable silencing, target engagement, and acceptable safety profiles.

Key Regional Insights

North America remains a leading RNA interference technology hub due to the presence of major biotechnology ecosystems, FDA experience with oligonucleotide therapeutics, strong venture financing, academic medical centers, and deep clinical trial infrastructure. Europe benefits from the European Medicines Agency pathway, academic excellence, national genomic medicine initiatives, and cross-border research programs, while the European Union supports harmonized standards for advanced therapeutics, pharmacovigilance, and pharmaceutical manufacturing.

Asia-Pacific is becoming increasingly influential as China expands biopharmaceutical innovation and nucleic acid drug development, Japan supports advanced therapy adoption through mature regulatory and clinical systems, India scales contract research and manufacturing capacity, South Korea invests in biotech platforms, and Australia maintains strong early-phase clinical trial capabilities. Latin America is led by Brazil and Mexico in clinical access and research participation, while the Middle East is building genomics-led healthcare systems, especially across GCC markets. Africa shows long-term potential in infectious disease, agriculture, and public health applications of RNA interference technology, though infrastructure, affordability, cold-chain logistics, and specialist access constraints remain material.

Key Group Insights

The G7 countries are central to RNAi commercialization because they combine mature regulators, reimbursement systems, intellectual property protection, advanced clinical networks, and established pharmaceutical manufacturing standards. The European Union strengthens consistency through coordinated regulatory oversight, multinational research funding, health technology assessment collaboration, and quality frameworks for medicines, while NATO-aligned markets add resilience priorities related to biomanufacturing, health security, strategic stockpiles, and supply chain continuity.

BRICS markets are strategically important for future RNAi scale because China, India, and Brazil offer large patient populations, expanding biotech investment, and growing manufacturing capabilities, while Russia and South Africa contribute scientific capacity under more variable access conditions. ASEAN is gaining relevance through Singapore-led biomedical research and growing clinical activity in Thailand, Malaysia, Vietnam, the Philippines, and Indonesia. The GCC is advancing precision medicine through national genomics programs, specialty care investment, digital health infrastructure, and partnerships that support access to advanced RNAi therapeutics.

Key Country Insights

The United States leads global RNA interference technology development through FDA-approved siRNA therapeutics, major biotechnology clusters, NIH-backed research, specialized clinical investigators, and capital access. Canada contributes strong academic science, publicly supported genomics research, and clinical research networks, while Mexico is an important access and trial market in North America. Brazil anchors Latin American opportunity through its healthcare scale, public research institutions, specialist hospitals, and experience in complex biologics access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support RNAi adoption through advanced clinical centers, established pharmaceutical ecosystems, rare disease networks, and payer evaluation systems, while Russia maintains scientific capabilities but faces market-access and geopolitical constraints. China is rapidly expanding RNAi pipelines, clinical trial activity, and biomanufacturing capacity; India is strengthening cost-efficient research, production, and contract development capabilities; Japan emphasizes high-quality clinical translation, regulatory rigor, and specialty medicine adoption; Australia supports early-phase trials through efficient clinical infrastructure; and South Korea is building competitive biotech platforms in nucleic acid medicines, precision medicine, and advanced manufacturing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize delivery platforms that extend RNAi beyond the liver while maintaining validated safety, reproducible manufacturing, and clear pharmacodynamic evidence. Organizations should invest in GalNAc, lipid nanoparticles, local delivery, ligand discovery, endosomal escape technologies, and scalable oligonucleotide synthesis to protect differentiation as competition increases.

Strategic success will depend on disciplined indication selection, payer-ready value evidence, and regulatory alignment from early development. Leaders should combine AI-enabled discovery with wet-lab validation, build regional clinical partnerships, secure resilient raw-material and oligonucleotide supply, strengthen quality systems, and prepare market-access strategies that demonstrate durable outcomes, reduced dosing burden, and measurable healthcare-system value.

Research Methodology

A structured methodology combining secondary research, primary interviews, data triangulation, and expert validation supports the assessment of RNA interference technology. Inputs include regulatory approvals, clinical trial registries, scientific literature, patent activity, company disclosures, government health data, reimbursement signals, public funding initiatives, and biopharmaceutical investment trends relevant to RNA interference technology.

The analysis evaluates technology maturity, delivery platforms, therapeutic pipelines, regional adoption, competitive positioning, regulatory requirements, manufacturing readiness, and commercialization barriers. Findings are cross-verified against public agency records, peer-reviewed evidence, clinical databases, and market participants' perspectives to ensure that conclusions are data-backed, current, and suitable for decision-making, without relying on market sizing, share estimates, or forecasts.

Conclusion

RNA interference technology has transitioned from a breakthrough biological discovery into a clinically validated modality with expanding commercial relevance. Approved siRNA therapeutics have confirmed that targeted gene silencing can deliver durable benefits, while advances in delivery systems are opening new disease areas and broader patient populations.

The next phase of leadership will be determined by extrahepatic delivery, AI-supported discovery, manufacturing scalability, regulatory, safety monitoring, and evidence-based reimbursement. Organizations that integrate scientific rigor with a regional access strategy will be best positioned to capture value in RNAi therapeutics, functional genomics, agricultural biotechnology, and next-generation precision medicine.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. RNA Interference Technology Market, by Molecule Type

  • 7.1. MicroRNA (miRNA)
  • 7.2. Short Hairpin RNA (shRNA)
    • 7.2.1. Non-Viral Delivery shRNA
    • 7.2.2. Viral Delivery shRNA
  • 7.3. Small Interfering RNA (siRNA)
    • 7.3.1. Conjugated siRNA
    • 7.3.2. Non-Conjugated siRNA

8. RNA Interference Technology Market, by Route Of Administration

  • 8.1. Intramuscular (IM) Injection
  • 8.2. Intrathecal (IT) Administration
  • 8.3. Intravenous (IV) Injection

9. RNA Interference Technology Market, by Delivery Method

  • 9.1. Direct Naked RNAi Delivery
  • 9.2. Exosome-Based RNAi Therapy
  • 9.3. Nanoparticle-Based Delivery
  • 9.4. Viral Vector-Based Delivery

10. RNA Interference Technology Market, by Application

  • 10.1. Drug Discovery
    • 10.1.1. Lead Optimization
    • 10.1.2. Target Identification
  • 10.2. Research & Development
    • 10.2.1. Gene Function Studies
    • 10.2.2. Pathway Analysis
  • 10.3. Therapeutics

11. RNA Interference Technology Market, by End-User

  • 11.1. Contract Research Organizations
  • 11.2. Hospitals & Clinics
  • 11.3. Pharmaceutical & Biotechnology Companies

12. RNA Interference Technology Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. RNA Interference Technology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. RNA Interference Technology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. ADARx Pharmaceuticals Inc
  • 16.2. Alnylam Pharmaceuticals Inc
  • 16.3. Arbutus Biopharma Corporation
  • 16.4. Arcturus Therapeutics Holdings Inc
  • 16.5. Arrowhead Pharmaceuticals Inc
  • 16.6. AstraZeneca PLC
  • 16.7. Avidity Biosciences Inc
  • 16.8. Benitec Biopharma Inc
  • 16.9. BioNTech SE
  • 16.10. City Therapeutics Inc
  • 16.11. Genevant Sciences Ltd
  • 16.12. Intellia Therapeutics Inc
  • 16.13. Ionis Pharmaceuticals Inc
  • 16.14. Moderna Inc
  • 16.15. Novartis AG
  • 16.16. Novo Nordisk A/S
  • 16.17. OliX Pharmaceuticals Inc
  • 16.18. Phio Pharmaceuticals Corp
  • 16.19. ProQR Therapeutics NV
  • 16.20. Roche Holding AG
  • 16.21. Sanofi SA
  • 16.22. Sarepta Therapeutics Inc
  • 16.23. Silence Therapeutics PLC
  • 16.24. Sirnaomics Inc
  • 16.25. Suzhou Ribo Life Science Co., Ltd
  • 16.26. Vir Biotechnology Inc
  • 16.27. Wave Life Sciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MICRORNA (MIRNA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MICRORNA (MIRNA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MICRORNA (MIRNA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SHORT HAIRPIN RNA (SHRNA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHORT HAIRPIN RNA (SHRNA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SHORT HAIRPIN RNA (SHRNA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-VIRAL DELIVERY SHRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-VIRAL DELIVERY SHRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-VIRAL DELIVERY SHRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL DELIVERY SHRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL DELIVERY SHRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL DELIVERY SHRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SMALL INTERFERING RNA (SIRNA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SMALL INTERFERING RNA (SIRNA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SMALL INTERFERING RNA (SIRNA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONJUGATED SIRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONJUGATED SIRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONJUGATED SIRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-CONJUGATED SIRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-CONJUGATED SIRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-CONJUGATED SIRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAMUSCULAR (IM) INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRAMUSCULAR (IM) INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAMUSCULAR (IM) INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRATHECAL (IT) ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRATHECAL (IT) ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRATHECAL (IT) ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAVENOUS (IV) INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAVENOUS (IV) INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAVENOUS (IV) INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIRECT NAKED RNAI DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIRECT NAKED RNAI DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIRECT NAKED RNAI DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EXOSOME-BASED RNAI THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EXOSOME-BASED RNAI THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EXOSOME-BASED RNAI THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NANOPARTICLE-BASED DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NANOPARTICLE-BASED DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NANOPARTICLE-BASED DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTOR-BASED DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTOR-BASED DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTOR-BASED DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE FUNCTION STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE FUNCTION STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE FUNCTION STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PATHWAY ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PATHWAY ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PATHWAY ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 154. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 155. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 157. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 160. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 174. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 175. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 181. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 184. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 185. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 187. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 190. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 191. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 194. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 195. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 197. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 200. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 215. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 216. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 285. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 286. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 305. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 306. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 312. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 315. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 316. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 322. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN RNA INTERFERENCE TECH